Previous Close | 4.2450 |
Open | 4.2100 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 4.1350 - 4.2700 |
52 Week Range | 3.4100 - 7.5000 |
Volume | |
Avg. Volume | 31,652 |
Market Cap | 65.484M |
Beta (5Y Monthly) | -0.32 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Valbiotis (FR0013254851 - ALVAL, PEA/SME eligible), a commercially oriented Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces the results of the international Phase II/III REVERSE-IT study, demonstrating TOTUM•63's impressive efficacy on key markers of glucose metabolism, with efficacy results comparable to those of some leading anti-diabetic drugs,